New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
06:41 EDTCMRXChimerix initiated with a Buy at Canaccord
Target $34.
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent CMRX news | >>
October 13, 2014
07:17 EDTCMRXChimerix volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTCMRXPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTCMRXCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTCMRXNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTCMRXTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
17:14 EDTCMRXMarket ends week lower amid global growth worries
Subscribe for More Information
October 9, 2014
14:55 EDTCMRXHospital says deputy showing no signs of Ebola, AP reports
Subscribe for More Information
14:24 EDTCMRXCDC head compares Ebola to AIDS, Washington Post says
Subscribe for More Information
14:13 EDTCMRXFirst Ebola vaccine trial in West Africa started, NBC News reports
Subscribe for More Information
12:06 EDTCMRXLakeland Industries continues surge amid Ebola fears
Subscribe for More Information
October 8, 2014
12:25 EDTCMRXOn The Fly: Midday Wrap
Subscribe for More Information
12:01 EDTCMRXChimerix plunges after first U.S. Ebola patient dies, levels to watch
The shares are down 11.5% to $29.38 following news that the first U.S. Ebola patient, Thomas Eric Duncan, has died. Duncan was being treated with the company's experimental Ebola drug, Brincidofovir. Based on current price, next support is at $27.62. Resistance is at $30.06 and then at $30.70.
11:55 EDTCMRXChimerix options active after Ebola patient taking experimental drug dies
Subscribe for More Information
11:52 EDTCMRXChimerix shares to be volatile as stock tracks Ebola news, says Piper Jaffray
Piper Jaffray noted the move lower in Chimerix following news that a patient in Texas that was being treated with its brincidofovir drug has died and said the stock will now be in a "much more volatile position" as its movements track news on the Ebola outbreak and treated patients. The firm believes the drug's usefulness in treating Ebola will need to be defined by more data and trials and that its established utility in other diseases provides value above the stock's current levels. Piper maintains its Overweight rating on shares of Chimerix.
11:22 EDTCMRXChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
11:17 EDTCMRXChimerix down 4% after Texas Ebola patient dies
Subscribe for More Information
10:18 EDTCMRXChimerix price target raised to $47 from $34 at Stifel
Subscribe for More Information
09:53 EDTCMRXChimerix price target raised to $41 from $37 at Piper Jaffray
Subscribe for More Information
09:20 EDTCMRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:36 EDTCMRXChimerix's Brincidofovir for adenovirus shows positive Phase 3 survival results
Chimerix announced preliminary data for its investigational antiviral brincidofovir showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. The preliminary survival analysis data showed a mortality rate of 35% vs. historic rates of up to 80% mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus. The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events.
1 | 2 | all recent CMRX news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use